When did QUOIN PHARMACEUTICALS LT-ADR (QNRX) report earnings last quarter?
QUOIN PHARMACEUTICALS LT-ADR (QNRX) last reported earnings on 3/26/2026.
NASDAQ:QNRX • US74907L4095
Past quarterly earnings results for QUOIN PHARMACEUTICALS LT-ADR (QNRX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -1.50 | -3.40 | 55.93% | 87.76% | - | - | ||
| Q3 2025 | -6.71 | -5.08 | -32.19% | 59.21% | - | - | ||
| Q2 2025 | -6.28 | -7.56 | 16.91% | 53.99% | - | - | ||
| Q1 2025 | -6.50 | -6.19 | -5.04% | 83.27% | - | - | ||
| Q4 2024 | -12.25 | -16.42 | 25.40% | 83.17% | - | - | ||
| Q3 2024 | -16.45 | -17.61 | 6.60% | 75.90% | - | - | ||
| Q2 2024 | -13.65 | -21.78 | 37.32% | 81.69% | - | - | ||
| Q1 2024 | -38.85 | -27.13 | -43.19% | 72.79% | - | - | ||
| Q4 2023 | -72.80 | -82.65 | 11.91% | 57.72% | - | - | ||
| Q3 2023 | -68.25 | -97.18 | 29.77% | 82.71% | - | - | ||
| Q2 2023 | -74.55 | -100.67 | 25.95% | 94.52% | - | - | ||
| Q1 2023 | -142.80 | -121.10 | -17.92% | 86.40% | - | - | ||
| Q4 2022 | -172.20 | -264.75 | 34.96% | 95.44% | - | - | ||
| Q3 2022 | -394.80 | -577.48 | 31.63% | 71.64% | - | - | ||
| Q2 2022 | -1,360.80 | -1,320.92 | -3.02% | - | - | - | ||
| Q1 2022 | -1,050.00 | -1,419.08 | 26.01% | - | - | - | ||
| Q4 2021 | -3,775.28 | - | - | - | - | |||
| Q3 2021 | -1,392.30 | - | - | - | - | |||
| Q2 2021 | - | - | - | - | ||||
| Q1 2021 | - | - | - | - | ||||
| Q4 2020 | - | - | - | - | ||||
| Q3 2020 | - | - | - | - | ||||
| Q2 2020 | - | - | - | - | ||||
| Q1 2020 | - | - | - | - |
Notes
QUOIN PHARMACEUTICALS LT-ADR (QNRX) last reported earnings on 3/26/2026.
QUOIN PHARMACEUTICALS LT-ADR (QNRX) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, QUOIN PHARMACEUTICALS LT-ADR (QNRX) has beaten EPS estimates in 2 out of 4 releases.